Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal

Clinical Infectious Diseases

Volumn 42, Issue 9, 2006, Pages 1247-1253

  Maskey, Ashish P ^a   Day, Jeremy N ^b,d,e   Tuan, Phug Quoc ^b   Thwaites, Guy E ^b   Campbell, James I ^b,c   Zimmerman, Mark ^a   Farrar, Jeremy J ^b,c   Basnyat, Buddha ^a  

^a PATAN HOSPITAL   (Nepal)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; GATIFLOXACIN; NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALMONELLOSIS VACCINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD CULTURE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEPAL; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH; SALMONELLA ENTERICA; SALMONELLA PARATYPHI; SALMONELLA TYPHI; SALMONELLOSIS; SCHOOL CHILD; SEROTYPE; TYPHOID FEVER; VACCINATION;

EID: 33646110272     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/503033     Document Type: Article

References (33)

1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346-53.
2. Murdoch DR, Woods CW, Zimmerman MD, et al. The etiology of febrile illness in adults presenting to Patan Hospital in Katmandu, Nepal. Am J Trop Med Hyg 2004; 70:670-5.
3. Sood S, Kapil A, Dash N, Das BK, Goel V, Seth P. Paratyphoid fever in India: an emerging problem. Emerg Infect Dis 1999; 5:483-4.
4. Tankhiwale SS, Agrawal G, Jalgaonkar SV. An unusually high occurrence of Salmonella enterica serotype paratyphi A in patients with enteric fever. Indian J Med Res 2003; 117:10-2.
5. Chandel DS, Chaudhry R, Dhawan B, Pandey A, Dey AB. Drug-resistant Salmonella enterica serotype paratyphi A in India. Emerg Infect Dis 2000; 6:420-1.
6. Saxena SN, Sen R. Salmonella paratyphi A infection in India: incidence and phage types. Trans R Soc Trop Med Hyg 1966; 60:409-11.
7. Abucejo PE, Capeding MR, Lupisan SP, et al. Blood culture confirmed typhoid fever in a provincial hospital in the Philippines. Southeast Asian J Trop Med Public Health 2001; 32:531-6.
8. Gillespie S. Salmonella infection. In: Cook GC, ZumLa A, eds. Manson's tropical diseases. 21st ed. Philadelphia: WB Saunders, 2003:937-49.
9. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005; 366:749-62.
10. Gadeholt H, Madsen ST. Clinical course, complications and mortality in typhoid fever as compared with paratyphoid b. A survey of 2647 cases. Acta Med Scand 1963; 174:753-60.
11. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 2002; 347:1770-82.
12. Wain J, Kidgell C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Trans R Soc Trop Med Hyg 2004; 98:423-30.
13. Frenck RW Jr, Nakhla I, Sultan Y, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis 2000; 31:1134-8.
14. Tatli MM, Aktas G, Kosecik M, Yilmaz A. Treatment of typhoid fever in children with a flexible-duration of ceftriaxone, compared with 14-day treatment with chloramphenicol. Int J Antimicrob Agents 2003; 21:350-3.
15. Dutta P, Mitra U, Dutta S, De A, Chatterjee MK, Bhattacharya SK. Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children. Indian J Med Res 2001; 113:210-3.
16. Acharya G, Butler T, Ho M, et al. Treatment of typhoid fever: randomized trial of a three-day course of ceftriaxone versus a fourteen-day course of chloramphenicol. Am J Trop Med Hyg 1995; 52:162-5.
17. Wallace MR, Yousif AA, Mahroos GA, et al. Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever. Eur J Clin Microbiol Infect Dis 1993; 12:907-10.
18. Chinh NT, Parry CM, Ly NT, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother 2000; 44:1855-9.
19. Frenck RW Jr, Mansour A, Nakhla I, et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 2004; 38:951-7.
20. Threlfall EJ, Fisher IS, Berghold C, et al. Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001. Int J Antimicrob Agents 2003; 22:487-91.
21. NCCLS. Performance standards for antimicrobial susceptibility testing: 13th informational supplement. NCCLS document M100-S13 (M7). Wayne, PA: NCCLS, 2003.
22. Schwartz E, Shlim DR, Eaton M, Jenks N, Houston R. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal. Arch Intern Med 1990; 150:349-51.
23. Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of school-children with parenteral typhoid vaccine. Rev Infect Dis 1987; 9:841-5.
24. Vollaard AM, Ali S, van Asten HA, et al. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA 2004; 291:2607-15.
25. Parry C, Wain J, Chinh NT, Vinh H, Farrar JJ. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 1998; 351:1289.
26. Harish BN, Madhulika U, Parija SC. Isolated high-level ciprofloxacin resistance in Salmonella enterica subsp. enterica serotype Paratyphi A [letter]. J Med Microbiol 2004; 53:819.
27. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 2003; 37:75-81.
28. Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S. Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 1999; 353: 1590-1.
29. Wain J, Hoa NT, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25:1404-10.
30. Slinger R, Desjardins M, McCarthy AE, et al. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis 2004; 4:36.
31. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother 2003; 47:827-9.
32. Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P. Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 1999; 37:3572-7.
33. International Vaccine Institute. Typhoid fever. http://www.ivi.org/pro gram/domi_typhoid.htmL. Accessed 11 March 2006.